Core Insights - Dianthus Therapeutics, Inc. is advancing its investigational monoclonal antibody, claseprubart, aimed at treating generalized Myasthenia Gravis (gMG) and will present Phase 2 trial results at the AANEM Annual Meeting [1][2] Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team from the biotech and pharmaceutical sectors [5] Product Details - Claseprubart (DNTH103) is designed to selectively inhibit the active form of the C1s protein, targeting the classical complement pathway, which is significant in autoimmune disease pathology [3] - The drug incorporates YTE half-life extension technology for convenient subcutaneous self-administration [3] - Claseprubart has the potential to be a best-in-class treatment across various autoimmune disorders with high unmet medical needs [3] Upcoming Events - The results from the Phase 2 MaGic trial will be presented on October 29, 2025, during the MGFA Scientific Session [2] - A virtual industry forum titled "Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition" will also take place on the same day, featuring an expert panel [2]